NCT06827262 Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
| NCT ID | NCT06827262 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Scientific Corporation |
| Condition | Chronic Low-back Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-03-26 |
| Primary Completion | 2034-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2025-03-26 with a primary completion date of 2034-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Eligibility Criteria
Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU). * Signed a valid, IRB/EC-approved informed consent form. Exclusion Criteria: * Meets any contraindications per locally applicable Instructions for Use (IFU).
Contact & Investigator
Natalie Bloom Lyons, M.A.
STUDY DIRECTOR
Boston Scientific Corporation
Frequently Asked Questions
Who can join the NCT06827262 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Low-back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06827262 currently recruiting?
Yes, NCT06827262 is actively recruiting participants. Contact the research team at BSNClinicalTrials@bsci.com for enrollment information.
Where is the NCT06827262 trial being conducted?
This trial is being conducted at Flagstaff, United States, Phoenix, United States, Larkspur, United States, Westport, United States and 11 additional locations.
Who is sponsoring the NCT06827262 clinical trial?
NCT06827262 is sponsored by Boston Scientific Corporation. The principal investigator is Natalie Bloom Lyons, M.A. at Boston Scientific Corporation. The trial plans to enroll 1,500 participants.